[Association between very low density lipoprotein cholesterol and cholesterol absorption/synthesis markers in patients with moderate and high risk of coronary heart disease].

Abstract

OBJECTIVE:

To evaluate the association between very low density lipoprotein cholesterol (VLDL-C) and cholesterol absorption and synthesis markers in patients with moderate and high risk of coronary heart disease.

METHODS:

A total 363 statin-naïve patients with moderate and high risk of coronary heart disease were consecutively recruited from two hospitals in Shanxi and Henan provinces between October 2008 and June 2009. A standard questionnaire and physical examination were performed at baseline. Atorvastatin (20 mg/day) was administered to patients for 4 weeks. Venous blood samples after an overnight fast were collected before and after treatment for measuring VLDL-C and cholesterol absorption and synthesis markers. In qualitative analyses, the baseline level of cholesterol absorption and synthesis markers and their reduction after atorvastatin treatment were categorized into 3 tertile groups.

RESULTS:

(1) Of 363 patients, 283 patients with mean age of (55.43±9.01)years old with complete data were finally analyzed. The median level of baseline VLDL-C was 1.06 (0.65, 1.86) mmol/L. The median level of baseline cholesterol absorption marker (Campesterol) and cholesterol synthesis marker (Lathosterol) was 6.01 (3.78, 9.45) mg/L and 13.46 (8.30, 21.07) mg/L, respectively. (2) Partial correlation analysis and multiple regression showed the baseline level of VLDL-C was positively correlated with Campesterol (r=0.153, P<0.05) but not with Lathosterol(r=0.182, P=0.173). Furthermore, baseline VLDL-C level significantly increased with tertile of the baseline level of Campesterol in the qualitative analyses(P for trend=0.035). (3) Mean reduction in VLDL-C levels was 38.0% after 4 weeks atorvastatin treatment. VLDL-C reduction was positively correlated with Campesterol reduction (r=0.331, P<0.001). VLDL-C reduction significantly increased with the tertile of Campesterol reduction (P for trend=0.032). But this trend was not observed between VLDL-C level and Lathosterol (P for trend=0.798).

CONCLUSION:

The level of VLDL-C was closely related to cholesterol absorption marker, and further studies are needed to validate if inhibitor of cholesterol absorption (for example by Ezetimibe) could bring about more effective VLDL-C lowering effect in this patient cohort.

• Authors: Zhizhong Gong, Yue Qi, Fan Zhao, Jing Liu, Wei Wang, Jun Liu, Jiayi Sun, Wuxiang Xie, Yan Li, Miao Wang, Lanping Qin, Ying Wang, Yongchen Hao, Qingxuan Zhang, Xiaoping Chen, Dong Zhao
• Journal: Zhonghua xin xue guan bing za zhi (Zhonghua Xin Xue Guan Bing Za Zhi) Vol. 43 Issue 11 Pg. 936-42 (Nov 2015) ISSN: 0253-3758 [Print] China
• PMID: 26888803 (Publication Type: Journal Article)

Chemical References

• Biomarkers
• Cholesterol, LDL
• Cholesterol, VLDL
• Hydroxymethylglutaryl-CoA Reductase Inhibitors
• Phytosterols
• campesterol
• lathosterol
• Cholesterol
• Atorvastatin
• Ezetimibe

Topics

• Atorvastatin
• Biomarkers
• Cholesterol (analogs & derivatives)
• Cholesterol, LDL
• Cholesterol, VLDL
• Coronary Artery Disease
• Ezetimibe
• Humans
• Hydroxymethylglutaryl-CoA Reductase Inhibitors
• Phytosterols
• Risk Factors